Ketamine metabolomics in the treatment of major depression

Anesthesiology

Volumn 121, Issue 1, 2014, Pages 4-5

  Van Velzen, Monique ^a   Dahan, Albert ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; HYDROXYNORKETAMINE; KETAMINE; MAMMALIAN TARGET OF RAPAMYCIN; MICROSOME ENZYME; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINIC RECEPTOR; PLACEBO; UNCLASSIFIED DRUG;

ANESTHESIST; ANTIDEPRESSANT ACTIVITY; BIPOLAR DEPRESSION; COGNITION; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; EDITORIAL; EMOTION; ENANTIOMER; ENANTIOSELECTIVITY; HUMAN; LIMBIC SYSTEM; LIVER MICROSOME METABOLISM; MAJOR DEPRESSION; METABOLOMICS; MOOD; NONHUMAN; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RACEMIC MIXTURE;

ANIMALS; EXCITATORY AMINO ACID ANTAGONISTS; KETAMINE; MALE; TOR SERINE-THREONINE KINASES;

EID: 84902782324     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0000000000000286     Document Type: Editorial

References (11)

1. van Dorp, Kest B, Kowalczyk WJ, Morariu AM, Waxman AR, Arout CA, Dahan A, Sarton E: Morphine-6-glucuronide rapidly increases pain sensitivity independently of opioid receptors in mice and humans. Anesthesiology 2009; 110:1356-63
2. Paul RK, Singh NS, Khadeer M, Moaddel R, Sanghvi M, Green CE, O'Loughlin K, Torjman MC, Bernier M, Wainer IW: (R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)- hydroxynorketamine increase the mammalian target of rapamycin function. Anesthesiology 2014; 121:149-59
3. S igtermans MJ, van Hilten JJ, Bauer MC, Arbous MS, Marinus J, Sarton EY , Dahan A: Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain 2009; 145:304-11
4. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47:351-4
5. Murrough JW: Ketamine as a novel antidepressant: From synapse to behavior. Clin Pharmacol Ther 2012; 91:303-9
6. Duman RS, Aghajanian GK: Synaptic dysfunction in depression: Potential therapeutic targets. Science 2012; 338:68-72
7. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS: mTO R-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329:959-64
8. Moaddel R, Abdrakhmanova G, Kozak J, Jozwiak K, Toll L, Jimenez L, Rosenberg A, Tran T, Xiao Y, Zarate CA, Wainer IW: Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in 7 nicotinic acetylcholine receptors. Eur J Pharmacol 2013; 698:228-34
9. Niesters M, Martini C, Dahan A: Ketamine for chronic pain: Risks and benefits. Br J Clin Pharmacol 2014; 77:357-67
10. Leung LY , Baillie TA: Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine. J Med Chem 1986; 29:2396-9
11. Zhang JC, Li SX, Hashimoto K: R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav 2014; 116:137-41